Antivirals targeting paramyxovirus membrane fusion.

Autor: Contreras EM; Department of Microbiology and Immunology, College of Veterinary, Cornell University, Ithaca, NY 14853, USA., Monreal IA; Department of Microbiology and Immunology, College of Veterinary, Cornell University, Ithaca, NY 14853, USA., Ruvalcaba M; Department of Microbiology and Immunology, College of Veterinary, Cornell University, Ithaca, NY 14853, USA., Ortega V; Department of Microbiology and Immunology, College of Veterinary, Cornell University, Ithaca, NY 14853, USA., Aguilar HC; Department of Microbiology and Immunology, College of Veterinary, Cornell University, Ithaca, NY 14853, USA. Electronic address: ha363@cornell.edu.
Jazyk: angličtina
Zdroj: Current opinion in virology [Curr Opin Virol] 2021 Dec; Vol. 51, pp. 34-47. Date of Electronic Publication: 2021 Sep 27.
DOI: 10.1016/j.coviro.2021.09.003
Abstrakt: The Paramyxoviridae family includes enveloped single-stranded negative-sense RNA viruses such as measles, mumps, human parainfluenza, canine distemper, Hendra, and Nipah viruses, which cause a tremendous global health burden. The ability of paramyxoviral glycoproteins to merge viral and host membranes allows entry of the viral genome into host cells, as well as cell-cell fusion, an important contributor to disease progression. Recent molecular and structural advances in our understanding of the paramyxovirus membrane fusion machinery gave rise to various therapeutic approaches aiming at inhibiting viral infection, spread, and cytopathic effects. These therapeutic approaches include peptide mimics, antibodies, and small molecule inhibitors with various levels of success at inhibiting viral entry, increasing the potential of effective antiviral therapeutic development.
(Copyright © 2021. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: